News & Events

Retina Congress

New York, New York

September 30 - October 4

American Academy of Ophthalmology

San Francisco, California

October 23 - 27

Retina 2010

Kauai, Hawaii

January 17-22, 2010

Macula Society

Tucson, Arizona

February 24 - 27, 2010

 

See all News & Events

Understanding AMD

Learn about the causes of wet AMD and why it's important to understand current treatment options.

NeoVista leadership

An experienced management team, dedicated venture partners — and a growing list of NeoVista accomplishments.

Innovations

NeoVista's proprietary technology makes epiretinal beta radiation therapy a potential addition to wet AMD treatment options.

CABERNET

This important clinical study is now under way; learn more about its design and key endpoints.

About Wet AMD

NeoVista, Inc., is dedicated to the development of medical technologies that help to advance the treatment of wet age-related macular degeneration (AMD). Wet AMD affects more than 5 million people around the world and is a major cause of blindness in men and women over the age of 50.

The unique technology being developed by NeoVista continues to show promise in clinical studies. It is our goal to help improve the quality of care and reduce the burden of this destructive condition on patients, physicians, and the healthcare system.

Learn more about wet AMD.

Learn more about NeoVista, Inc.

Learn more about epiretinal beta radiation therapy, our innovative core technology.

Learn more about current clinical trials of NeoVista technology.

 

In the News

Sky News - Radiation Beams Used To Restore Eyesight
Saturday November 21, 2009
Thomas Moore, health correspondent

German Television - Makula-Degeneration: Neue Behandlung rettet Augenlicht

 

Videos & Animations

New Multimedia Section
  • Visit our new Multimedia page, with video presentations and animated procedures available for viewing.